Albright AL, Gregg EW Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program. Am J Prev Med. 2013 Apr;44(4 Suppl 4):S346-51. doi: 10.1016/j.amepre.2012.12.009.
Barlow SE; Expert Committee Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007 Dec;120 Suppl 4:S164-92.
Centers for Disease Control and Prevention National Diabetes Prevention Program 2017. Available at: https://www.cdc.gov/diabetes/prevention/index.html [Accessed on October 18, 2017]
Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health. 2012 Jul;102(7):1274-81. doi: 10.2105/AJPH.2012.300755. Epub 2012 May 17.
Institute of Medicine (IOM) Accelerating Progress in Obesity Prevention: Solving the Weight of the Nation. Health and Medicine Division (eds), National Academies Press, May 8, 2012.
O'Connor EA, Evans CV, Burda BU, Walsh ES, Eder M, Lozano P Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Jun 20;317(23):2427-2444. doi: 10.1001/jama.2017.0332. Review.
Wilfley DE, Vannucci A, White EK Early intervention of eating- and weight-related problems. J Clin Psychol Med Settings. 2010 Dec;17(4):285-300. doi: 10.1007/s10880-010-9209-0. Review.
World Health Organization (WHO) BMI classification. 2006 Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html [Accessed on October 18, 2017]
Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
